Cargando…

A single center experience of intravenous immunoglobulin treatment in Covid-19

BACKGROUND: Intravenous immunoglobulins (IVIg) have been used in management of severe Covid-19. Here in this study, we report our single-center experience regarding IVIg treatment in management of severe Covid-19. MATERIALS AND METHOD: Among hospitalized adult Covid-19 patients between April 1 and D...

Descripción completa

Detalles Bibliográficos
Autores principales: Omma, Ahmet, Erden, Abdulsamet, Armağan, Berkan, Güven, Serdar Can, Karakaş, Özlem, Şahiner, Enes Seyda, Erdem, Deniz, İzdeş, Seval, Ateş, İhsan, Küçükşahin, Orhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200303/
https://www.ncbi.nlm.nih.gov/pubmed/34153671
http://dx.doi.org/10.1016/j.intimp.2021.107891
_version_ 1783707576818466816
author Omma, Ahmet
Erden, Abdulsamet
Armağan, Berkan
Güven, Serdar Can
Karakaş, Özlem
Şahiner, Enes Seyda
Erdem, Deniz
İzdeş, Seval
Ateş, İhsan
Küçükşahin, Orhan
author_facet Omma, Ahmet
Erden, Abdulsamet
Armağan, Berkan
Güven, Serdar Can
Karakaş, Özlem
Şahiner, Enes Seyda
Erdem, Deniz
İzdeş, Seval
Ateş, İhsan
Küçükşahin, Orhan
author_sort Omma, Ahmet
collection PubMed
description BACKGROUND: Intravenous immunoglobulins (IVIg) have been used in management of severe Covid-19. Here in this study, we report our single-center experience regarding IVIg treatment in management of severe Covid-19. MATERIALS AND METHOD: Among hospitalized adult Covid-19 patients between April 1 and December 31, 2020, patients with confirmed diagnosis of Covid-19 who had Brescia-COVID respiratory severity scale score ≥ 3, hyperinflammation and received IVIg treatment in addition to standard of care were retrospectively investigated. We grouped IVIg recipients into three according to reasons for IVIg administration: Group 1 patients requiring anti-inflammatory treatment but complicated with secondary infection and/or sepsis , group 2 patients with Covid-19 related complications including progressive disease refractory to other anti-inflammatory agents, myocarditis, adult multisystem inflammatory syndrome, hemophagocytic lymphohystiocytosis like syndrome and group 3 patients with other complications non-specific to Covid-19. Mortality and clinical data was compared among groups. RESULTS: A total of 46 IVIg recipients were enrolled. Group 1 comprised 17 (36.9%), group 2 comprised 18 (39.1%) and group 3 comprised 11 (23.9%) patients. No significant differences in means of age, gender and comorbidities were observed among groups. Mortality was significantly lower in group 3 when compared to group 1 (64.7% vs 18.2%, p = 0.016) and close to significance when compared to group 2 (50% vs 18.2% p = 0.087). CONCLUSIONS: IVIg seemed to be used mostly in severe, refractory and complicated cases in our population. As a rescue agent in severe cases refractory to other anti-inflammatory strategies, 33.7% survival rate was observed with IVIg.
format Online
Article
Text
id pubmed-8200303
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-82003032021-06-15 A single center experience of intravenous immunoglobulin treatment in Covid-19 Omma, Ahmet Erden, Abdulsamet Armağan, Berkan Güven, Serdar Can Karakaş, Özlem Şahiner, Enes Seyda Erdem, Deniz İzdeş, Seval Ateş, İhsan Küçükşahin, Orhan Int Immunopharmacol Article BACKGROUND: Intravenous immunoglobulins (IVIg) have been used in management of severe Covid-19. Here in this study, we report our single-center experience regarding IVIg treatment in management of severe Covid-19. MATERIALS AND METHOD: Among hospitalized adult Covid-19 patients between April 1 and December 31, 2020, patients with confirmed diagnosis of Covid-19 who had Brescia-COVID respiratory severity scale score ≥ 3, hyperinflammation and received IVIg treatment in addition to standard of care were retrospectively investigated. We grouped IVIg recipients into three according to reasons for IVIg administration: Group 1 patients requiring anti-inflammatory treatment but complicated with secondary infection and/or sepsis , group 2 patients with Covid-19 related complications including progressive disease refractory to other anti-inflammatory agents, myocarditis, adult multisystem inflammatory syndrome, hemophagocytic lymphohystiocytosis like syndrome and group 3 patients with other complications non-specific to Covid-19. Mortality and clinical data was compared among groups. RESULTS: A total of 46 IVIg recipients were enrolled. Group 1 comprised 17 (36.9%), group 2 comprised 18 (39.1%) and group 3 comprised 11 (23.9%) patients. No significant differences in means of age, gender and comorbidities were observed among groups. Mortality was significantly lower in group 3 when compared to group 1 (64.7% vs 18.2%, p = 0.016) and close to significance when compared to group 2 (50% vs 18.2% p = 0.087). CONCLUSIONS: IVIg seemed to be used mostly in severe, refractory and complicated cases in our population. As a rescue agent in severe cases refractory to other anti-inflammatory strategies, 33.7% survival rate was observed with IVIg. Elsevier B.V. 2021-09 2021-06-14 /pmc/articles/PMC8200303/ /pubmed/34153671 http://dx.doi.org/10.1016/j.intimp.2021.107891 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Omma, Ahmet
Erden, Abdulsamet
Armağan, Berkan
Güven, Serdar Can
Karakaş, Özlem
Şahiner, Enes Seyda
Erdem, Deniz
İzdeş, Seval
Ateş, İhsan
Küçükşahin, Orhan
A single center experience of intravenous immunoglobulin treatment in Covid-19
title A single center experience of intravenous immunoglobulin treatment in Covid-19
title_full A single center experience of intravenous immunoglobulin treatment in Covid-19
title_fullStr A single center experience of intravenous immunoglobulin treatment in Covid-19
title_full_unstemmed A single center experience of intravenous immunoglobulin treatment in Covid-19
title_short A single center experience of intravenous immunoglobulin treatment in Covid-19
title_sort single center experience of intravenous immunoglobulin treatment in covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200303/
https://www.ncbi.nlm.nih.gov/pubmed/34153671
http://dx.doi.org/10.1016/j.intimp.2021.107891
work_keys_str_mv AT ommaahmet asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT erdenabdulsamet asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT armaganberkan asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT guvenserdarcan asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT karakasozlem asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT sahinerenesseyda asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT erdemdeniz asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT izdesseval asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT atesihsan asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT kucuksahinorhan asinglecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT ommaahmet singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT erdenabdulsamet singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT armaganberkan singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT guvenserdarcan singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT karakasozlem singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT sahinerenesseyda singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT erdemdeniz singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT izdesseval singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT atesihsan singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19
AT kucuksahinorhan singlecenterexperienceofintravenousimmunoglobulintreatmentincovid19